Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
46-Year-Old Sharjah Resident With Uncontrolled Glaucoma Successfully Treated With Microshunt Surgery At Aster Hospital Al Qusais
Aster Hospital Al Qusais, recognized in Newsweek's“World's Best Smart Hospitals 2025” List among 350 hospitals globally and ...
Healio20d
Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...
Nasdaq13d
Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
The EYLEA HD results were consistent across patients with branch retinal vein occlusions ... of EYLEA HD in its pivotal trials. Ocular treatment-emergent adverse events (TEAEs) occurring in ...
Healio21d
Retina360: Advances in the Treatment of Retinal Vein Occlusion
In this CE activity, experts in the field will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. In support of improving ...
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to ...
Managed Healthcare Executive3d
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
The Bakersfield Californian13d
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema ...
TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® ...